Melanoma Care: A Mixed Bag for Australian Patients

Melanoma patients in Australia have been receiving mixed signals when it comes to a crucial diagnostic test. A recent study looked at the uptake of sentinel lymph node biopsy (SLNB) among patients with invasive melanoma. The results showed that while the number of melanoma diagnoses and SLNB procedures increased over time, the proportion of patients undergoing SLNB remained stable. In fact, the average proportion of patients who received a SLNB during the study period was around 36%. But what's surprising is that this proportion remained relatively low despite evolving clinical practice guidelines. So, what's behind this mixed bag of results?

The study found that factors like age, Breslow thickness, body site, melanoma subtype, socio-economic status, and geographic remoteness all played a role in determining whether patients received a SLNB. For instance, patients living outside major cities and those with greater socio-economic disadvantage were less likely to receive the test. These findings suggest that there may be inequities in care for melanoma patients in Australia. It's a concerning trend that highlights the need for better access to diagnostic tests and more equitable care for all patients.